In Vitro Evaluation and In Vivo Pharmacokinetic Assessment of Intranasal Tadalafil Nanocrystals
Abstract
Tadalafil (TDA), a Biopharmaceutics Classification System (BCS) class II drug, exhibits poor aqueous solubility but high permeability. This study focused on enhancing the bioavailability of poorly soluble TDA through the development of intranasal nanocrystals (NCs). TDA NCs stabilized with polyvinyl alcohol (PVA) demonstrated the smallest particle size and optimal solubility. Formulation F11 measured 196 nm in size, with a polydispersity index (PDI) of 0.21 and a zeta potential of -11.20, showin
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.